PTC Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

CEO

Matthew B. Klein

CEOMatthew B. Klein

Employees

991

Employees991

Headquarters

Warren, New Jersey

HeadquartersWarren, New Jersey

Founded

1998

Founded1998

Employees

991

Employees991

PTCT Key Statistics

Market cap

6.54B

Market cap6.54B

Price-Earnings ratio

-33.34

Price-Earnings ratio-33.34

Dividend yield

—

Dividend yield—

Average volume

2.19M

Average volume2.19M

High today

$78.85

High today$78.85

Low today

$76.57

Low today$76.57

Open price

$77.90

Open price$77.90

Volume

1.36M

Volume1.36M

52 Week high

$90.87

52 Week high$90.87

52 Week low

$43.18

52 Week low$43.18

Stock Snapshot

With a market cap of 6.54B, PTC Therapeutics(PTCT) trades at $78.06. The stock has a price-to-earnings ratio of -33.34.

During the trading session on 2026-07-15, PTC Therapeutics(PTCT) shares reached a daily high of $78.85 and a low of $76.57. At a current price of $78.06, the stock is +1.9% higher than the low and still -1.0% under the high.

Trading volume for PTC Therapeutics(PTCT) stock has reached 1.36M, versus its average volume of 2.19M.

The stock's 52-week range extends from a low of $43.18 to a high of $90.87.

PTCT News

TipRanks 11h

PTC Therapeutics price target raised to $95 from $93 at BofA

BofA raised the firm’s price target on PTC Therapeutics (PTCT) to $95 from $93 and keeps a Buy rating on the shares. The firm, which conducted a survey of 20 ne...

Simply Wall St 1d

What PTC Therapeutics's Q1 Beat and Sephience Outlook Shift Mean For Shareholders

Earlier this week, PTC Therapeutics reported strong Q1 2026 earnings that surpassed analyst expectations, alongside insider stock sales executed under pre-arran...

Nasdaq 2d

What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million

Key Points The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighte...

Analyst ratings

73%

of 15 ratings

Buy

73.3%

Hold

20%

Sell

6.7%

People also own

Based on the portfolios of people who own PTCT. This list is generated using Robinhood data, and it’s not a recommendation.

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.